Detection reagent and therapeutic target for B cell tumor after targeted therapy and related application
US11953500B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 25, 2022 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | Jul 21, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2469/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a detection reagent and therapeutic target for B cell tumor after targeted therapy and related applications. The reagent composition comprises 3 groups of antibodies, with the first group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD24 an antibody, an anti-CD20 antibody, an anti-CD81 antibody, an anti-CD45 antibody; the second group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD20 antibody, an anti-CD72 antibody, an anti-CD45 antibody; and the third group of antibodies including an anti-cytoplasmic CD79a antibody. The reagent composition of the present invention can be applied for the detection of B-lymphocyte tumors after targeted therapy by flow cytometry.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.